Symbols

AMAM(Delisted)

Ambrx Biopharma·NASDAQ

--(--)

Key Stats

0.0000DAY`S RANGE0.0000

0.000052 WK RANGE0.0000

Open

0.0000

Prev.Close

0.0000

%Range

Turnover

Avg Vol(4W)

Market Cap

Div.Yield

P/E(TTM)

EPS(TTM)

Beta

Free Float

Shares Outstanding

%Turnover

P/E(DYN)

P/B

BVPS

High

0.0000

Low

0.0000

52 Week High

0.0000

52 Week Low

0.0000

About AMAM

Ambrx Biopharma, Inc.

A clinical stage biopharmaceutical company that developing antibody drug conjugates

Industry

Established Date

Listing Date

03/17/2023

Exchange

NASDAQ Stock Exchange

Full-time Employees

Fiscal Year Ends

12-31

Website

www.ambrx.com

Security Type

Common stock

Office address

10975 North Torrey Pines Road, La Jolla, California, United States 92037

Business

Introduction

Ambrx Biopharma, Inc., is a corporation organized under the laws of the State of Delaware. The Company is a clinical-stage biologics company focused on the discovery and development of a new class of engineered precision biologics (EPBs), leveraging its proprietary Extended Genetic Code technology platform that enables them to integrate synthetic amino acids (SAAs) into proteins within living cells in a site-specific manner. Their product candidates are designed to overcome the inherent limitations of traditional binding methods that use natural amino acids for non-site-specific binding, providing potential safety and efficacy benefits for the treatment of patients across multiple therapeutic areas.

Company Financials

EPS

AMAM has released its 2023 Q3 earnings. EPS was reported at -0.37, versus the expected -0.19, missing expectations. The chart below visualizes how AMAM has performed over recent quarters, highlighting trends in earnings surprises.

Revenue & Expenses

AMAM has released its 2023 Q3 earnings report, with revenue of 53.00K, reflecting a YoY change of -96.68%, and net profit of -22.99M, showing a YoY change of -47.67%. The Sankey diagram below clearly presents AMAM's revenue sources and cost distribution.